Prevention of fungal infections in children and adolescents with cancer;Präivention von pilzinfektionen bei kindern und jugendlichen mit neoplastischen erkrankungen

Klinische Padiatrie

Volumn 213, Issue SUPPL. 1, 2001, Pages

  Groll, A H ^a   Ritter, J ^b   Muller F M C ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Amphotericin; Aspergillus; Cancer; Candida; Children; Fluconazole; Itraconazole; Mycoses; Prophylaxis; Stem cell transplantation

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANCER PATIENT; CHILDHOOD CANCER; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION CONTROL; MYCOSIS; OPPORTUNISTIC INFECTION; ADOLESCENT; ADULT; AGE; APLASTIC ANEMIA; ARTIFICIAL VENTILATION; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMMUNE DEFICIENCY; INFANT; MORTALITY; NEOPLASM; NEUTROPENIA; NEWBORN; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AMPHOTERICIN B; ANEMIA, APLASTIC; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOUBLE-BLIND METHOD; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; ITRACONAZOLE; MYCOSES; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY THERAPY; RISK FACTORS; TIME FACTORS;

EID: 0034828943     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17502     Document Type: Article

References (184)

1. Aspergillosis in children with cancer: A 34-year experience
2. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis
3. Primary cutaneous aspergillosis associated with Hickman intravenous catheters
4. Opportunistic mycoses in the immunocompromised host: Ex-perience at a cancer center and review
5. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
6. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections
7. Predictors of adverse outcome in cancer patients with candidemia
8. Aspergillus species aerosols in hospitals: Showering as a potential source of exposure abstr, 1908
9. Antifungal antibiotics. Itraconazole
10. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: A double-blind, randomized, controlled clinical study
11. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers
12. Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma
13. Systemic Candida infection in pediatric BM autotransplantation: Clinical signs, outcome and prognosis
14. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis
15. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients
16. Hepatosplenic candidiasis - A contraindication to marrow transplantation?
17. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B
18. Fungal infections complicating acute leukemia
19. The emergence of fungi as major hospital pathogens
20. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies
21. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels
22. Pharmacokinetics of fluconazole in pediatric patients
23. Efficacy, safety, and pharmacokinetics of intravenous followed by oral itraconazole in patients with invasive pul-monary aspergillosis
24. In vitro antifungal activity of liposomal nystatin in comparison with nys-tatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, am-photericin B lipid complex, amphotericin B deoxycholate, fluconazole and itraconazole
25. Guidelines for prevention of nosocomial pneumonia
26. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
27. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
28. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis
29. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients
30. Administration of itraconazole for antifungal prophylaxis in stem cell transplant recipients: Levels and drug interactions
31. Aspergillus infection prophylaxis: Amphotericin B nasal spray, a double blind trial
32. Acquired itraconazole resistance in Aspergillus fumigatus
33. Itraconazole: Pharmacology, clinical experience and future development
34. Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: A single center experience from 1980 to 1995
35. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children
36. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for invasive aspergillosis
37. An EORTC multicentre prospective survey of invasive aspergillosis in haemato-logical patients: Diagnosis and therapeutic outcome
38. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
39. Invasive aspergillosis
40. Invasive aspergillosis: Host defenses
41. Incidence of polyene-resistant yeasts recovered from clinical specimens
42. Development of vaccines and their use in the prevention of fungal infections
43. The physiologic effects of inhaled amphotericin B
44. Detection and identification of fungal pathogens in blood by using molecular probes
45. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
46. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients
47. Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study
48. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours
49. Oropharyngeal candidiasis in immunocompromised children: A randomized, multicenter study of orally administered fluconazole suspension versus nystatin
50. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders
51. Itraconazole through concentrations in anti-fungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules
52. Definition of itraconazole target concentration for antifungal prophylaxis
53. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia
54. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?
55. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
56. Clinical features and analysis of risk factors for invasive Candidal infection after marrow transplantation
57. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses
58. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
59. Amphotericin B and pulmonary surfactant
60. Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer
61. Five-year survey of invasive aspergillosis in a pediatric cancer center: Incidence, clinical presentation, management, and long-term survival
62. Pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with HIV infection and oropharyngeal candidiasis
63. Lipid formulations of Amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer
64. Fortschritte in praevention und therapie infektioeser komplikationen bei kindern und jugendlichen mit neoplastischen erkrankungen
65. Antifungal pharmacodynamics. Concentration-effect relationships in vitro and in vivo
66. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
67. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
68. Antifungal Triazoles
69. Potential new antifungal agents
70. Primary cutaneous aspergillosis in six leukemic children
71. The toxicity of daily inhaled amphotericin B
72. Risk factors for fungal infection in patients with malignant hematologic disorders: Implications for empirical therapy and prophylaxis
73. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
74. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B
75. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia
76. Lipid formulations of amphotericin B: Recent progress and future directions
77. Fluconazole versus itraconazole for the prevention of fungal infections in haematooncology
78. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics
79. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole
80. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients
81. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients
82. Hepatosplenic candidiasis: Successful treatment with fluconazole
83. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study
84. Deep Candida infection in children receiving allogeneic bone marrow transplants: Incidence, risk factors and diagnosis
85. Deep Candida infection in children with leukaemia: Clinical presentations, diagnosis and outcome
86. Vascular catheter-associated fungemia in cancer patients: Analysis of 155 episodes
87. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
88. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
89. Haematopoetische wachstumsfaktoren
90. Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancer
91. Update on drug interactions with azole antifungal agents
92. Antifungal prophylaxis during neutropenia and immunodeficiency
93. Risk factors for candidemia in a children's hospital
94. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis
95. Systemic candidiasis in cancer patients
96. Candida tropicalis and Candida albicans fungemia in children with leukemia
97. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
98. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
99. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature
100. Ambisome vs. fluconazole plus itraconazole prophylaxis in frintline therapy of acute myelogenous leukemia and myelodysplastic syndrome
101. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B
102. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
103. Candidiasis
104. New methods for delivery of antifungal agents
105. Fungemia in the immuno-compromised host. Changing patterns, antigenemia, high mortality
106. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia
107. Fungal infections in bone marrow transplant patients
108. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies
109. Current approaches in diagnosis and treatment of fungal infections in HIV-infected children
110. Adherence and invasion-two pathogenicity factors in bacterial and fungal pathogens
111. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis
112. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia
113. The changing face of candidemia: Emergence of non- Candida albicans species and antifungal resistance
114. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies
115. Safety and tolerability of fluconazole in children
116. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients
117. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients
118. Impact of previous aspergillosis on the outcome of bone marrow transplantation
119. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
120. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients
121. Antifungal prophylaxis: To prevent or not
122. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia
123. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: A critical reassessment
124. Prophylaxis of fungal infections with itraconazole during remission-induction therapy
125. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe
126. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
127. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
128. Pharmacokinetics of itraconazole (oral solution) in two groupos of human immunodeficiency virus-infected adults with oral candidiasis
129. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients
130. Special aspects related to invasive fungal infections in children with cancer
131. Update on invasive candidiasis
132. The role of immunoreconstitution in the management of refractory opportunistic fungal infections
133. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis
134. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
135. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation
136. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): Aerosol characteristics and in-vivo amphotericin B deposition in rats
137. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
138. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients
139. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
140. Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis
141. Prophylaxis of oropharyngeal candidiasis with fluconazole
142. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus
143. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias
144. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis
145. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis
146. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial
147. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study
148. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis
149. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria
150. Itraconazole in cyclodextrin solution
151. Nystatin prophylaxis in immunocompromised children
152. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial
153. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies
154. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients
155. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies
156. Successful program to prevent Aspergillus infections in children undergoing marrow transplantation: Use of nasal amphotericin
157. Aerosolized amphotericin B in prophylaxis of pulmonary aspergillosis
158. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
159. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal
160. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients
161. Pathogenesis, host resistance, and predisposing factors
162. Bloodstream infections in children with cancer: A multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology
163. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study
164. Epidemiology of Asper-gillus infections in a large cohort of patients undergoing bone marrow transplantation
165. Invasive Aspergillus infections in a pediatric hospital: A ten-year review
166. Nosocomial aspergillosis: Environmental micro-biology, hospital epidemiology, diagnosis and treatment
167. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century
168. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
169. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
170. Prevention of invasive fungal infections in patients with neoplastic disease
171. Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
172. New targets and delivery systems for antifungal therapy
173. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis
174. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia
175. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal Candidiasis
176. Risk factors for hospital-acquired candidemia. A matched case-control study
177. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
178. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
179. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
180. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy
181. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial
182. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group
183. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia
184. Pulmonary cryptococcosis associated with cryptococcal meningitis in non-AIDS patients: Four case reports and a review of the literature